Clopidogrel and Warfarin related gene detection kit

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. CYP2C19 is the primary metabolizing enzyme of S-warfarin. Compared to patients homozygous for CYP2C19*1, individuals who inherit one or two copies of CYP2C19*2 or *3 are at greater risk of bleeding during warfarin therapy, require lower doses to achieve similar levels of anticoagulation, and require more time to achieve a stable INR. VKORC1 encodes the vitamin K epoxide reductase protein, the target enzyme of warfarin. A common variant upstream of VKORC1 (c.-1639G>A, rs9923231) is significantly associated with warfarin sensitivity. Clopidogrel is commonly prescribed for ACSs and/or following PCI. Clopidogrel is a thienopyridine prodrug that requires CYP2C19 enzyme to form an active metabolite and drug response varies due to CYP2C19 gene polymorphism.

The wild-type CYP2C19*1 allele is associated with functional CYP2C19-mediated metabolism. The most common CYP2C19 loss-of-function alleles are *2 and *3, which can reduce active clopidogrel metabolites and higher on-treatment platelet aggregation as compared with *1 homozygotes. By contrast, the CYP2C19*17 allele has higher activity, which results in enhanced platelet inhibition and clopidogrel response, and perhaps, an increased risk of bleeding complications.

Features

➢    Accurate

Genotype genes responsible for Clopidogrel and Warfarin metabolism.

➢    Sensitive

Requires only 1 ng DNA.

➢    Easy-to-use

Applicable for automatic and batched detection for samples directly amplified from saliva/blood card or EDTA-anticoagulated blood tube.

➢    Fast

Get results within 3 hours, with manual operation time of 20 minutes. 

 

Workflow

 

Sample types

Peripheral blood, blood stain

Loci detected

 

Instrument

Gene analyzer (ABI PRISM 310, 3100 Genetic Analyzer, or ABI 3130 Series, 3500 Series, 3730 Series Genetic Analyzer)